The determinants of the research agenda

Gross CP , Anderson GF , Powe NR The relation between funding by the National Institutes of Health and the burden of disease. N Engl J Med 1999; 340: 1881 - 7.

Varmus H. Evaluating the burden of disease and spending the research dollars of the National Institutes of Health. N Engl J Med 1999; 340: 1914 - 15.

Pollard MR Pharmaceutical innovation in the United States: factors influencing future performance. Int J Techn Ass Health Care 1993 ; 9: 167 - 73.

Grossman JH Introduction (to Industry and the generation of technology). Int J Technology Ass Health Care 1993; 9: 157 - 61.

Griffin J. The madness of industries mega mergers. Scrip 1996; May: 10 - 11.

Henry D. , Lexchin J. The pharmaceutical industry as a medicines provider. Lancet 2002; 360: 1590-5.

Vos R. Drugs looking for diseases. Thesis, University of Groningen 1989.

Anonymous. The tightening grip of big pharmaceutical companies. Lancet 2001; 357: 1141.

Kiln M. Industry-sponsored research. Lancet 2001; 357: 1209.

Wessely S. Peer review of grant applications: what do we know? Lancet 1998; 352: 301 - 5.

Lotz P. Demand as a driving force in medical innovation. Int J Techn Ass Health Care 1993; 9: 174 - 88.

Horton R. Medical journals: evidence of bias against the diseases of poverty . Lancet 2003; 361: 712 - 13.

Ezzati M. , Lopez AD , Rodgers A. , Vander Hoorn S. , Murray CJL , and the comparative risk assessment collaborating group. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347 - 60.

Farmer P. Can transnational research be ethical in the developing world? Lancet 2002; 360: 1266.